A health economics study, Integrating a Polygenic Risk Score for Coronary Artery Disease as a Risk‐Enhancing Factor in the Pooled Cohort Equation: A Cost‐Effectiveness Analysis Study, has been published in the Journal of the American Heart Association. The study, performed by Allelica Health Economist, Deo Mujwara, in collaboration with experts from Illumina and the University of Sydney, analyzed the cost-effectiveness of PRS in heart disease risk assessments and found that PRS is cost-saving in US health systems.

Allelica CSO, George Busby, presented his latest work on breast cancer PRS, Genetic assessments of breast cancer risk that do not account for polygenic background are incomplete and lead to incorrect preventative strategies, at the 2022 ESHG Conference in Vienna, Austria. The presentation highlighted the potential of PRS to improve risk assessment for breast cancer and the risks of looking at monogenic mutations alone.

Allelica Health Economist, Dr. Deo Mujwara, will be presenting the results of a cost-effectiveness analysis of PRS for heart disease in a US Health System setting at the ISPOR annual conference. The Allelica team will join Deo at the conference as exhibitors to spread the word of the power of PRS to reduce the burden of heart disease while saving money.

Allelica will participate in the 2022 American Association for Cancer Research Annual Meeting. Researchers and physicians from across the world will gather to discuss breakthroughs in pathology, early detection and treatment. The Allelica team will provide attendees with information on how PRS can radically improve cancer risk assessments.

Allelica participated in the 2022 ACMG Annual Clinical Genetics Meeting in Nashville, TN. The Allelica team was able to network with industry leaders and discuss the power of Polygenic Risk Score in clinical practice.

Allelica continues to set the industry standard of clinical-grade Polygenic Risk Score analysis with the addition of two key ISO certifications. ISO 13485 and ISO 9001 certify that Allelica applies medical device quality management processes every step of the way.

Allelica hosted a Genomeweb webinar on the clinical application of Polygenic Risk Score in risk assessments. Speakers included Dr. Pradeep Natarajan from the Massachusetts General Hospital, Dr. Noura Abul-Husn from the Icahn School of Medicine at Mount Sinai and Allelica CSO, Dr. George Busby.

Allelica is joining forces with world leaders in genomic medicine at Congenica to provide an educational webinar focused on Polygenic Risk Score in clinical application. The speakers will cover the opportunities and challenges to widespread implementation for PRS in the UK and beyond.

Alongside international scientists, Allelica CSO, George Busby, presented on PRS at the largest genomics conference in Latin America. George discussed how PRS is applied in non-European populations and how PRS modulates penetrance of single gene mutations.

Together with researchers at University of Sydney and Illumina, Inc., Allelica researchers and health economist, Deo Mujwara, completed a study on the cost-saving power of PRS for health systems. The study focuses on application of PRS in heart disease risk assessments, specifically looking at the advantages of using PRS as a risk enhancing factor in the Pooled Cohort Equation.

Alongside the three leading cardiovascular scientific societies in Italy, Allelica hosted a press conference focused on the commercialization of CardioriskSCORE, the CAD PRS developed by Allelica and published in Circulation. Participants discussed the impact this has on heart attack risk and its implications for more effective primary prevention strategies. The conference was attended by top cardiologists and pharmaceutical companies in Europe.

In the Spring 2021 edition, Pharmafile magazine interviewed Allelica CEO, Giordano Bottà, on the critical role Polygenic Risk Score plays in assessing patients’ risk of heart disease. The interview covers the process of PRS integration in existing cardiovascular disease risk assessment, and discusses how Allelica is helping to power rapid adoption of PRS for complex disease in the clinic.

Allelica CSO, George Busby, presented on the increasingly important role of polygenic risk scores in precision medicine in the UK and beyond, highlighting the challenges and opportunities for PRS implementation at scale. The webinar was hosted by the Oxford Personalised Medicine Society, part of the Wellcome Trust Centre for Human Genetics & University of Oxford.

Allelica CEO and co-founder, Giordano Bottà, was interviewed as part of an editorial piece, Polygenic Risk Scores: Taking Hold in the Clinic, in the most recent version of Clinical Omics. He discusses the growing importance of PRS in healthcare and the opportunities it presents for chronic disease prevention.

Allelica researchers identified a critical interaction between PRS for coronary artery disease (CAD) and LDL cholesterol level. Their discovery has major implications for clinical decision-making in primary prevention strategies. The research is now available in the American Heart Association Journal, Circulation.

This event will showcase emerging and innovative applications advancing consumer & healthcare genomics to accelerate the adoption of precision medicine in healthcare systems. We will be discussing the life-saving potential of PRS for heart disease and its power to advance personalized lipid management.

Formed earlier this year, the COVID-19 Host Genetics Initiative is an open collaboration between scientists around the globe. It is focused on identifying genetic determinants of disease susceptibility and severity in order to understand why symptoms manifest in such drastically different ways. As participants in the initiative, we are developing scores to predict disease severity. e also built web and mobile digital tools to collect data from hospitalized patients.

Our newest product for healthcare providers calculates patients’ lifetime risk of developing coronary artery disease based on the integration of genetic and traditional risk factors using state of the art polygenic risk score. The interactive tool shows patients how manageable lifestyle changes and therapeutic interventions can actively lower lifetime risk of heart disease.

The Rady Children's Institute for Genomic Medicine Virtual Conference 2020, Integrating Genomic Medicine Across Systems, will dive deep into the latest innovations in genomic medicine. We will show our work alongside leaders in research and healthcare on how early polygenic risk score testing can reduce the lifetime risk of coronary artery disease.

We are proud to have been selected as a “Reviewer's Choice” by the American Society of Human Genetics, being rated among the top 10% of abstracts. Our work will be presented at the ASHG Virtual Meeting 2020 where researchers will come together to present their latest discoveries and explore new tools & technologies to transform genomic medicine.

We are very excited to announce our participation in the 16th World Congress of Public Health, a conference which brings together some of the brightest minds and latest scientific developments from across the globe. Our presentation will focus on the role of polygenic risk scores in the prevention of common adult onset conditions.